Top 20 Biologics 2007 RD Pipeline News

1/20 La Merie S.L. | Email [email protected]

| Internet www.lamerie.com

TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1

TOP 20 Biologics 2007

• TOP 20 Blockbuster Drugs 2007

• TOP 13 Biologics Classes 2007

• Blockbuster Biologics 2007 by Class • Selected Other Recombinant Biologics

• Selected Other Non-Recombinant Biologics

Features:

March 27, 2008 Special Edition 1

March 27, 2008

Subscribe now!

http://www.pipelinereview.com/joomla/index.php?option=com_yanc&Itemid=133&listid=1&action=subscribe

2/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com


TOP 20 Biologics in 2007 ID No.

Product Name

Target / Mechanism of Action

Class of Compound

Company Product Category

Indication 2007 sales (vs 2006)

1 epoetin alfa; Epogen / ESPO / Procrit / Eprex

EPO-R Rhu protein Amgen & Kirin & Johnson & Johnson

Protein Renal and cancer anemia

US$ 5,764 mln (US$ 6,024)

2 etanercept; Enbrel / Embrel

TNF-alpha Rec fusion protein of Fc + sol TNF-R

Amgen & Wyeth & Takeda

Antibody Rheumatoid arthritis; psoriasis etc

US$ 5,453 mln (US$ 4,474)

3 rituximab; Rituxan / MabThera

CD20 Rec chimeric mab

Genentech/ Roche /Chugai Biogen IDEC, Zenyaku Kogyu

Antibody 1st line treat-ment of diffuse, large B-cell, CD20+ NHL plus chemotherapy

US$ 5,392 mln (US$ 3,912)

4 trastuzumab Herceptin

HER2 Rec huma-nized mab

Roche / Genentech

Antibody Metastatic breast cancer

US$ 4,743 mln (US$ 3,175)

5 infliximab Remicade;

TNF-alpha Rec chimeric mab

Centocor (J&J) & Schering-Plough & Tan-abe Seiyaku

Antibody Rheumatoid arthritis etc

US$ 4,465 mln (US$ 3,764)

6 bevacizumab Avastin

VEGF Rec humanized mab

Roche & Genentech

Antibody Metastatic colorectal cancer

US$ 4,014 mln (US$ 2,395)

7 darbepoetin Aranesp / NESP

EPO-R Rhu glycol-engineered protein

Amgen & Kirin Pharma


US$ 4,004 mln (US$ 4,121)

8 insulin analog glargine ; Lantus

Insulin receptor

Rhu insulin analog

Sanofi-Aventis Protein Diabetes mellitus

US$ 3,167 mln (US$ 2,188)

9 adalimumab; Humira

TNF-alpha Rec fully human mab

Abbott (& Eisai)

Antibody Rheumatoid arthritis, psoriasis etc

US$ 3,064 mln (US$ 2,044)




Product Name


Class of Compound



10 Neulasta; peg-filgrastim

G-CSF-receptor

Pegylated rhu protein

Amgen Protein Neutropenia US$ 3,000 mln (US$ 2,710)

11 insulin analogs aspart / determir; Levemir; NovoLog (Mix)

Insulin receptor

Rhu insulin analogues

Novo Nordisk Protein Diabetes US$ 2,929 mln (US$ 1,908)

12 Human insulin; Actrapid / Novolin; Insulatard; Mixtard

Insulin receptor

Rhu proteins NovoNordisk Protein Diabetes US$ 2,629 mln (US$ 2,653)

13 epoetin beta; Neo-recormon / Epogin

EPO-R Rhu protein Roche & Chugai


US$ 2,047 mln (US$ 1,794)

14 interferon beta-1a Rebif

IFN-R Rhu protein Merck Serono Protein Multiple sclerosis US$ 1,875 mln (US$ 1,804)

15 inteferon beta-1a; Avonex

IFN-R Rhu protein Biogen Idec Protein Multiple sclerosis US$ 1,868 mln (US$ 1,707)

16 interferon beta-1b; Betaferon / Betaseron;

IFN-R Rhu protein Bayer Schering Pharma

Protein Multiple sclerosis US$ 1,603 mln (US$ 1,545)




Product Name


Class of Compound



17 peginterfer-on alfa-2a; Pegasys

IFN-R Pegylated rec hu protein

Roche Protein Hepatitis B and C

US$ 1,600 mln (US$ 1,186)

18 Insulin analog lispro Humalog

Insulin receptor

Rhu insulin analog

Eli Lilly Protein Diabetes US$ 1,475 mln (US$ 1,300)

19 filgrastim Neupogen / GRAN

G-CSF-receptor

Rhu protein Amgen & Kirin Protein Neutropenia US$ 1,419 mln (US$ 1,344)

20 cetuximab Erbitux

EGF-R Rec chimeric mab

Bristol-Myers Squibb & Merck Serono (from ImClone)

Antibody Refractory meta-static colorectal cancer; Head & neck cancer

US$ 1,416 mln (US$ 1,095)



No. Previous

Year Class of Products 2007 sales

(US$ bln.) Change vs

2006 Selected Branded Products

1 2 Major cancer antibodies 15.74 + 48 % Rituxan/MabThera, Herceptin, Avastin, Erbitux, Vectibix

2 3 Anti-TNF antibodies 12.98 + 26.3 % Enbrel, Remicade, Humira

3 1 Erythropoietins 11.82 - 1 % Aranesp, Procrit Eprex, Epogen, Neo-Recormon, ESPO

4 4 Insulin and insulin analogs 11.19 + 24.7 % Humalog, Humulin, Lantus, Levemir, Novorapid, Actrapid, Novolin

5 5 Rec. coagulation factors 5.39 + 14.4 % Novoseven, Kogenate, Helixate, Refacto, Advate, Recombinate, Benefix

6 6 Interferon beta 5.35 + 21.5 % Avonex, Rebif, Betaferon / Betaseron

7 7 G-CSF 4.82 + 10.4 % Neulasta, Neupogen, Neutrogin, GRAN

8 8 Human growth hormone 2.77 + 12.1 % Genotropin, Norditropin, Humatrope, Nutropin, Saizen, Serostim

9 9 Interferon alpha 2.74 + 21.4 % Pegasys, Peg-Intron, Intron A

10 10 Enzyme Replacement 2.29 + 34.1 % Cerezyme, Fabrazyme, Aldurazyme, Myozyme, Replagal, Naglazyme, Elaprase

11 - Ophthalmic antibody 1.36

- Lucentis

12 12 Follicel stimulating hormone

~ 1.28 + 21.8 % Gonal-f, Puregon/Follistim

13 11 Antiviral antibody > 1.13 + 2.3 % Synagis

Total:

78.86

+ 15 %



Product Type: Pharmaceutical Category: Cancer antibodies - No. 1

ID No.

Product Name


Class of Compound


Indication 1st approval

2007 sales (mln) vs. previous year (%)

Rituxan / MabThera; rituximab

CD20 Rec chimeric mab

Genentech/ Roche /Chugai Biogen IDEC Zenyaku Kogyu

Antibody 1st line treat-ment of diffuse, large B-cell, CD20+ NHL plus chemotherapy

1997 CHF 5,516 (+ 15 %) = US$ 5,392* source

Herceptin, trastuzumab

HER2 Rec humanized mab

Roche / Genentech

Antibody Metastatic breast cancer

CHF 4,852 (+ 23 %) = US$ 4,743* source

Avastin; bevacizumab

VEGF Rec humanized mab

Roche / Genentech

Antibody Metastatic colorectal cancer

CHF 4,106 (+ 41) = US$ 4,014* source

Erbitux; cetuximab

EGF-R Rec chimeric mab

Bristol-Myers Squibb & Merck Serono (from ImClone)

Antibody Refractory metastatic colorectal cancer; Head & neck cancer

BMS = US: US$ 692 (+ 6 %) source Merck Serono = Non-US: € 470 mln (+ 40 %) = US$ 724 source total Erbitux sales: US$ 1,416

Vectibix; panitumu-mab

EGF-R Rec fully human mab

Amgen Antibody 3rd line metastatic colorectal cancer

2006 US$ 170 (+ 336 %) source

Total: US$ 15,735

* strong influence of currency exchange rate (CHF into US$)

6

http://www.pipelinereview.com/database/files/Roche_2007_Results_Presentation_Jan_30__2008.pdf



http://www.pipelinereview.com/content/view/17530/298/

http://www.pipelinereview.com/press-room/merck-190208.pdf




Product Type: Pharmaceutical Category: Anti-TNF Biologics– No. 2

ID Product Target / Class of Company Product Indication 1st 2007 sales (mln) No. Name Mechanism Compound Category appr vs. previous year (%)

of Action oval Enbrel; TNF-alpha Fusion

protein of Fc + sol TNF-R

Amgen Fusion protein

Rheumatoid arthritis; psoriasis etc

North America: US$ 3,230 (+ 12 %) etanercept source

Ex-US and Canada: US$ 2,045 (+ 36 %)

Wyeth Fusion protein

Rheumatoid arthritis; psoriasis etc

Enbrel; TNF-alpha Fusion protein of Fc + sol TNF-R

(from Amgen) etanercept source

Fusion protein

Rheumatoid arthritis

03/ Q2-4: Y 14.3 bln Takeda Phar-maceuticals (from Wyeth)

Embrel; TNF-alpha Fusion protein of Fc + sol TNF-R

source 2005 etanercept Extrapolated Q1-4: Yen 19 bln (+

66.5 %) = US$ 177.6 Co-promotion with Wyeth KK

Remicade; infliximab


Centocor / J&J Antibody Rheumatoid arthritis etc

Exclusive US$ = 2,534 (+ 7.6 %) + Intl to partners (793: + 20.5 %)

(10 indications) Total: US$ 3,327 source Forecast fiscal year 2007: Antibody Rheumatoid

arthritis; psoriasis etc



Tanabe Seiyaku Yen 28.3 bln (+ 38 %)

= US$ 283 (from Centocor)

source for Japan and certain Asian countries



Schering-Plough

Antibody Rheumatoid arthritis; psoriasis etc

US$ 1,648 (+ 33 %*) source For non-US territory = RoW except US, Japan and certain Asian countries (Tanabe territories)

US$ 3,064 (+ 49.9 %) Humira TNF-alpha Rec fully human mab

Abbott Antibody Rheumatoid arthritis, psoriasis etc

source adalimumab (& Eisai) Approved in six indications

Total: US$ 12,982



http://www.takeda.com/pdf/usr/default/00_28962_1.pdf

http://www.jnj.com/news/jnj_news/pdf/kp0704h4s8a6g4.pdf

http://www.mt-pharma.co.jp/e/ir/meeting/pdf/e_presen071105_H.pdf

http://www.pipelinereview.com/database/files/Schering-Plough_Product_Sales_2007_Feb_12__2008.pdf




Product Type: Pharmaceutical Category: EPOs – No. 3

ID Product Target / Class of Company Product Indication 1st 2007 sales (mln) No. Name Mechanism

of Action Compound Category appr

oval vs. previous year (%)

Aranesp; darbepoetin

EPO-receptor Glyco-engineered rhu protein

Amgen Protein Renal and cancer anemia

US$ 3,614 (- 12 %) source

5

Kirin Pharma Protein Anemia 07/ 2007

Combined sales of ESPO + NESP: EPO-R Glyco-engineered rhu protein

NESP; (from Amgen) Yen 41.7 bln (+ 0.3 %) = US$ 390

mln darbepoetin; KRN321 source

Procrit / Eprex;

EPO-R Rhu protein Johnson & Johnson


US$ 2,885 (- 12 %) source

epoetin alfa (from Amgen) Epogen; EPO-R Rhu protein Amgen Protein Renal and

cancer anemia US$ 2,489 (- 1 %) source

epoetin alfa ESPO; EPO-R Rhu protein Kirin Pharma Protein Anemia Combined sales of ESPO + NESP:

epoetin alfa (from Amgen) Yen 41.7 bln (+ 0.3 %) = US$ 390 mln source > 50 % market share

EPO-R Rhu protein Roche & Chugai


NeoRecormon: CHF 1,536 (- 4 %) = US$ 1501

Neo-recormon / Epogin; Epogin: CHF 558 (- 14 %) = US$

545 epoetin beta Combined epoetin beta sales: CHF 2,094 (- 7 %) = US$ 2,047 source

Total: US$ 11,815


http://www.pipelinereview.com/database/files/Kirin_2007_Results_Statement_Feb_08__2007.pdf

http://www.jnj.com/news/jnj_news/pdf/kp0704h4s8a6g4.pdf






Product Type: Pharmaceutical Category: Insulin products – No. 4


of Action oval Humalog;

insulin lispro Insulin receptor

Rhu insulin analog

Eli Lilly Protein Diabetes US$ 1,475 (+ 13 %) source

Humulin Insulin receptor

Rhu insulin Eli Lilly Protein Diabetes US$ 985 (+ 6 %) source

Lantus; insulin glargine

Insulin receptor

Rhu insulin analog once daily

Sanofi-Aventis Protein Diabetes mellitus

€ 2,031 (+ 21.9 %) = US$ 3,167 source

Novo Nordisk Protein Diabetes Combined sales of Novo’s insulin analogs: DKK 14,008 (+ 29 %)

Levemir Insulin receptor

Rhu (basal) insulin analogue detemir

= US$ 2,929 source

Novo Nordisk Protein Diabetes NovoLog (Mix)

Insulin receptor

Rhu rapid acting insulin analogue aspart

Actrapid / Novolin; Insulatard; Mixtard

Insulin receptor

Rhu insulin and related products

Novo Nordisk Protein Diabetes Human insulins: DKK 12,572 (- 7 %) = US$ 2,629 source

Total: US$ 11,185

8



http://en.sanofi-aventis.com/Images/20-F_2007_secured_tcm24-20527.pdf

http://www.novonordisk.com/include/asp/exe_news_attachment.pdf?sAttachmentGUID=08ed30ae-5bd6-4fb6-a2ef-ec14e68be632




Product Type: Pharmaceutical Category: Rec. coagulation factors – No 5

ID Product Target / Class of Company Product Indication 1st 2007 sales (mln) No. Name Mechanism Compound Category appr vs. previous year

of Action oval NovoSeven; Coagulation

factor replacement

Rhu factor VIIa

Novo Nordisk Protein Hemophilia DKK 5,865 (+ 4 %) = US$ 1,226 eptacog alfa source

Bayer Schering Pharma

Protein Hemophilia A € 818 ( + 3.9 %) = US$ 1,276 Rhu factor VIII + need-le-free inject

Kogenate FS + BioSet;

Coagulation factor replacement

source octocog

Helixate FS Factor VIII substitution

Rhu factor VIII formul. with sucrose

CSL Behring Cardio-vascular & blood

Hemophilia A Fully year 2006/7: 17 % of AUS$ 2.6 bln (442) = US$ 403 mln (from Bayer

Schering) source (H2/2007 = AUS$ 228 = US$ 208 source )

Hemophilia A 2007 sales > US$ 1,200 Baxter Cardio-vascular & blood

Advate; Factor VIII substitution

Plasma + albumin free processed rhu protein

source rAHF

RecombinaterAHF

Factor VIII substitution

Rhu factor VIII

Baxter Cardio-vascular & blood

Hemophilia A Combined 2007 sales of Recombinate and Advate = US$ 1,714 mln (+ 13 %)

(from GI/Wyeth) source Wyeth Protein Hemophilia A US$ 335 (+ 9.6 %) Rhu B-dom-

ain deleted factor VIII

Refacto Coagulation factor replacement

source

Benefix; Coagulation factor replacement

Rhu factor IX Wyeth Protein Hemophilia B US$ 433 (+ 21 %) source transition of rights to Wyeth since July 2007 in EMEA states

Nonacog alfa reformulated

Hemophilia B < US$ 43 (all hospital distributed products incl. BeneFIX)

Cardio-vascular & blood

Baxter (exclusive in Europe)

BeneFIX; Substitution of factor IX

Rec human factor IX reformulated

Nonacog alfa - not considered - reformulated

Total: US$ 5,387


http://www.annualreport2007.bayer.com/en/bayer_annualreport_2007.pdfx

http://www.csl.com.au/docs/692/27/CSL_AR_2007.pdf

http://www.csl.com.au/docs/267/517/1H08%20results%20presentation%20FINAL%20NO%20NOTES.pdf

http://ccbn.10kwizard.com/xml/download.php?repo=tenk&ipage=5492526&format=PDF

http://ccbn.10kwizard.com/xml/download.php?repo=tenk&ipage=5492526&format=PDF

http://www.pipelinereview.com/database/files/Wyeth_2007_Sales_by_Products_Jan_2008.pdf




Product Type: Pharmaceutical Category: Interferon beta – No- 6


of Action oval Avonex;

inteferon beta-1a

IFN-R Rhu interferon β-1a

Biogen Idec Protein Multiple sclerosis US$ 1,868 (+ 9 %) source

Merck Serono & Pfizer

Protein Multiple sclerosis EURO 1,218 (+ 5.3 %)= US$ 1,875

IFN-R Rhu interferon β-1a

Rebif; interferon beta-1a

source reporting of Merck Serono includes Pfizer sales source

Bayer Schering Pharma

Protein Multiple sclerosis € 1,028 (+ 3.7 % pro forma) = US$ 1,603

IFN-R Rhu interferon β-1b

Betaferon / Betaseron; sourceinterferon beta-1b

Total: US$ 5,346



http://www.pipelinereview.com/database/files/Pfizer_2007_Annual_Review_Jan_2008.pdf

http://www.annualreport2007.bayer.com/en/bayer_annualreport_2007.pdfx



Product Type: Pharmaceutical

Category: G-CSF – No. 7


of Action oval US$ 3,000 (+ 10.7 %) Neulasta;

peg-filgrastim

G-CSF-receptor

Pegylated Amgen Protein Neutropenia associated with chemotherapy

source rhu protein

Neupogen / GRAN;

G-CSF-receptor

Rhu protein Amgen Protein Neutropenia associated with chemotherapy

Amgen: US$ 1,277 (+5.3 %) source

filgrastim Kirin: Yen 15.2 bln (- 1 %) = US$ 142 mln sourceTotal: US$ 1,419 mln

CHF 405 (+ 13%) = US$ 396

Neutrogin; G-CSF-receptor

Rhu protein Chugai Protein Neutropenia associated with chemotherapy

lenograstim (Roche) source

Total: > US$ 4,815

11

http://www.pipelinereview.com/database/files/Jan%2024,%202008%20AMGEN%20Supporting%20Materials.pdf

http://www.pipelinereview.com/database/files/Jan%2024,%202008%20AMGEN%20Supporting%20Materials.pdf





Product Type: Pharmaceutical Category: human Growth Hormone – No. 8


of Action oval Genotropin Regulation of

postnatal growth

Rec human protein

Pfizer Protein Growth hormone deficiency

US$ 843 (+ 6 %) source

Norditropin Regulation of postnatal growth

Rec human protein

Novo Nordisk Protein Growth hormone deficiency

DKK 3,511 (+ 6 %) = US$ 734 source

Rec human protein

Eli Lilly Protein Growth hormone deficiency

Estimate of US$ 441 (+ 6 % ) Humatrope; Regulation of postnatal growth

source

Nutropin; Protropin; somatropin; somatrem

Regulation of postnatal growth

Rec human protein

Genentech (Roche)

Protein Growth hormone deficiency

CHF 470 (- 1) = US$ 459 source

Protein Growth hormone deficiency

€ 23.7 (+ 61 %) = US$ 37 Rec human protein

Ipsen Nutropin AQ Pen; somatropin

Regulation of postnatal growth

(from Genen-tech / Roche)

source License for RoW except North America and Japan

Rec human protein

Merck Serono Protein Growth hormone deficiency

Saizen: EURO 163.1 (- 2 %) = US$ 254

Saizen / Regulation of postnatal growth

Serostim source

Total: US$ 2,768

1



http://www.pipelinereview.com/database/files/Lilly_Results_Sales_Jan_2008.xls


http://www.pipelinereview.com/press-room/Ipsen_Full_Year_2007_%20sales.pdf




Product Type: Pharmaceutical Category: Interferon alfa – No. 9

Product Target / Class of Company Product Indication 1st 2007 sales (mln) Name Mechanism Compound Category appr vs. previous year (%)

of Action oval Pegasys;

peginterfer-on alfa-2a

IFN-R Pegylated rec hu protein

Roche Protein Hepatitis B and C

CHF 1,637 (+ 11 %) = US$ 1,600 source

US$ 911 (+ 9 %) Peg-Intron; pegylated IFN alfa-2b

IFN-R Pegylated rhu protein

Schering-Plough

Protein Hepatitis C source

Intron A; interferon alfa-2b

IFN-R Rhu protein Schering- Plough

Protein Hepatitis US$ 233 (- 2 %) source

Total: US$ 2,744

1






Product Type: Pharmaceutical Category: Enzyme Replacement – No. 10

Product Target / Class of Company Product Indication 1st 2007 sales (mln) Name Mechanism Compound Category appr vs. previous year

of Action oval Cerezyme;

imiglucerase Beta-gluco-cerebrosidase replacement

Imiglucerase for injection

Genzyme Protein Gaucher’s disease

US$ 1,133 (+ 12.5 %) source

Rhu enzyme Genzyme Protein Fabry disease US$ 424 (+ 18.1 %) Fabrazyme; Alpha galactosidse A replacement

sourceagalsidase beta

Rhu enzyme Genzyme Protein Pompé disease US$ 201 (+ 239 % ) Myozyme; Acid-alpha-glucosidase replacement

sourcealglucosidase alfa

US$ 123.7 (+ 28.5 %) Aldurazyme; laronidase

Alpha-L-iduronidase replacement

Rhu enzyme Genzyme & BioMarin

Protein Hurler and Hurler-Scheie forms of mucopoly-

source Total product sales of Joint Venture

saccharidosis I (MPS I)

Elaprase; Iduronate-2-sulfatase replacement

Rhu enzyme Shire Protein Hunter syndrome

2006 US$ 181.8 (+ 670 %) source idursulfase (from TKT)

(MPS II) Replagal; Alpha-

galactosidase replacement

Rhu enzyme Shire & Protein Fabry disease US$ 143.9 (+ 22 %) sourceagalsidase alfa

Dainippon Sumitomo

In Japan approved in Oct 2007

Rhu enzyme BioMarin Protein MPS VI US$ 86.2 (+ 85.4 %) Naglazyme; N-acetyl-galactosamine 4-sulfatase replacement

sourcegalsulfase

Total: US$ 2,293.6

http://www.genzyme.com/corp/investors/genz_analyst_q4_2007.pdf




http://www.pipelinereview.com/press-room/shire_250208.pdf

http://www.pipelinereview.com/press-room/shire_250208.pdf




Product Type: Pharmaceutical Category: Ophthalmic antibody - 11


of Action oval Genentech for US: CHF 991 = US$ 969 (+ 117 %)

Lucentis; VEGF Rec humanized Fab

Genentech (Roche) & Novartis

Antibody Wet age-related macular degeneration

2006 US; 2007 EU

ranibizumab source Novartis for ex-US: US$ 393 source Total : US$ 1,362

Product Type: Pharmaceutical Category: Follicle stimulating hormones – No. 12


of Action oval Gonal-f;

follitropin alfa

FSH-R Rhu protein Merck Serono Protein Infertility EURO 434.2 (+ 2 %) = US$ 668 source

Puregon; Follistim follitropin beta

FSH-R Rhu protein Schering-Plough

Protein Infertility US$ 57 mln (from Nov 19 to Dec 31, 2007) source

(ex Organon) 2006 sales: € 384 (+ 8 %) = US$ 599 source

Approximately Total: US$ 1,267

Product Type: Pharmaceutical Category: Antiviral antibody – No. 13


of Action oval 1999 Jan – March 2007: US$ 507 Rec huma-

nized mab AstraZeneca (MedImmune)

Antibody Prevention of RSV in pre-mature infants

Synagis, Respiratory syncytical virus

source palivizumab June – Dec 2007: US$ 618 source

Total 2007 sales > US$ 1,125


http://www.pipelinereview.com/database/files/Novartis_Presentation_Results_2007_Pharma_Jan_17__2008.pdf



http://www.shareholder.com/Shared/DynamicDoc/akzo/1052/Q4report_engels.pdf

http://phx.corporate-ir.net/phoenix.zhtml?c=83037&p=irol-newsArticle&ID=993188&highlight

http://www.pipelinereview.com/press-room/astrazeneca-fourth-quarter-results-2007-narrative.pdf



Product Type: Pharmaceutical Category: Selected Other Recombinant Biologics

Product Name


Class of Compound




Forteo; teriparatide

PTH-R Rhu peptide (PTH 1-34)

Eli Lilly Peptide Osteoporosis US$ 709 (+ 19 %) source

Preotact (EU) / Preos (US)

PTH-R Rhu peptide (PTH 1-84)

Nycomed (from NPS Pharma-ceuticals)

Peptide Osteoporosis 2006 € 18 mln (+ 2,395 %) = US$ 28 source

Raptiva; efalizumab

CD11a Rec humanized mab

Genentech (Roche) & Merck Serono

Antibody Mild to moderate psoriasis

Roche: CHF 144 (+ 15 %) = US$ 141 source Ex-US : EURO 76.3 (+ 37 %) = US$ 117 source Total: US$ 258

Pulmozyme; dornase alfa

DNA Rhu protein Genentech (Roche)

Protein Cystic fibrosis CHF 483 (+ 12 %) = US$ 472 source

Orencia; abatacept

CD80/CD86 (B7.1 + B7.2)

Rec fusion protein of CTLA4 + Fc

Bristol-Myers Squibb

Fusion protein

Rheumatoid arthritis

2005 US$ 231 (+ 216 %) source

Xolair; omalizumab

IgE Rec humanized mab

Genentech (Roche) & Novartis

Antibody Asthma Roche: CHF 567 (+ 10 %) = US$ 554 source Novartis: US$ 140 (+ 30 %) sourceCombined : US$ 694

BMP-2; rhBMP2; InductOs

Tissue regeneration

Rhu growth factor

Wyeth Protein Spinal fusion + long bone fusion

US$ 359 (+ 16.5 %), mainly in US source

Activase / Alteplase; Metalyse / TNKase; tenecteplase

Plasminogen Rec hu protein or rhu mutant protein

Genentech (Roche) & Boehringer Ingelheim

Protein Acute myocardial infarction; ischemic stroke

Genentech: CHF 382 (+ 9 %) = US$ 373 source Boehringer Ingelheim 2006 sales of both proteins: EURO 159 source in H1/2007 – 11 %


http://www.nycomed.com/NR/rdonlyres/718AABC2-69E3-408D-9441-E7EB044FFACE/0/Nycomed_Company_Brochure_2008_EN.pdf






http://www.pipelinereview.com/database/files/Novartis_Presentation_Results_2007_Pharma_Jan_17__2008.pdf



http://www.boehringer-ingelheim.com/corporate/download/ar/BI_AR2006_en.pdf



Product Type: Pharmaceutical Category: Selected Other Recombinant Biologics

Product Name


Class of Compound




Tysabri; natalizumab

Alpha4 integrin

Rec humanized mab

Biogen Idec & Elan

Antibody Multiple sclerosis; Crohn’s disease

Biogen Idec: US$ 230 source Elan: US$ 343 source

Xigris; Drotrecogin alfa

Activated protein C

Rhu protein Lilly Protein High risk severe sepsis

US$ 182.8 (- 5 %) source

Actemra; tocilizumab

Interleukin-6 receptor

Rec humanized mab

Roche (Chugai)

Antibody Rheumatoid arthritis

CHF 5 = US$ 5 (+ 21 %) source







Product Type: Pharmaceutical Category: Selected Other Non-recombinant Biologics


of Action oval Copaxone; Immuno-

modulator Peptide Sanofi-Aventis

& Teva Peptide Multiple sclerosis 1997 (Sanofi-Aventis: EURO 1,177 (+

10.1 %) Glatiramer acetate

source ) Teva: global sales: US$ 1,713 (+ 21 %) source

Botox; botulinum toxin type A

Neuro-muscular blockade

Botulinum neurotoxin type A

Allergan & GSK (Japan and China)

Peptide Aesthetic and medical indications

Allergan: US$ 1,212 mln (+23.4 %) source ; Allergan receives royalties from GSK not included in sales figure

Botulinum neurotoxin type A

Dysport (EU); Reloxin (US); botulinum toxin type A

Neuro-muscular blockade

Medicis Peptide Aesthetic medicine indications

2007 sales of € 128.7 mln (+ 13.6 %) (NA + J) & source

Galderma (EU)

(from Ipsen)

Byetta; GLP-1 receptor

GLP-1 analog Eli Lilly & Amylin Phar-maceuticals

Peptide Diabetes 2005 US$ 650 (+ 48 %) sourceexenatide

Fuzeon, HIV entry inhibitor

Linear 36-aa synthetic peptide

Roche & Trimeris

Peptide HIV CHF 320 (+ 3 %) = US$ 313 enfuvirtide source

Integrilin GP IIb/IIIa Peptide Schering-Plough

Peptide Acute coronary syndrome

US$ 332 (+ 1 %) source

ReoPro; GP IIb/IIIa Peptide Lilly Peptide Acute coronary syndrome

US$ 270.3 (- 4 %) sourceabciximab

http://en.sanofi-aventis.com/Images/20-F_2007_secured_tcm24-20527.pdf


http://agn360.client.shareholder.com/earningsReleasedetail.cfm?ReleaseID=290764

http://www.pipelinereview.com/press-room/Ipsen_Full_Year_2007_%20sales.pdf







Why should you use R&D Pipeline N ?

Learn more about R&D Pipeline News

• To keep up-to-date.

R&D Pipeline News is your weekly tool for biopharmaceutical R&D analysis and it's available by annual subscription.

Examine the who, what, when, where of biotechnology R&D.

R&D Pipeline News will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a given Target, Technology or Company.

• To benchmark your company against the competition

Keep en eye on your competitors’ projects and developments, in which stage they are, their achievements, handicaps, etc…and find out where you are standing in the market. The R&D information is presented in an easy- and rapid-to-

screen tabular format and grouped either in Therapeutic Areas or Product Categories, saving you time in your research.

• To save time in your research

Get the crucial information, in a one-shot tabular screen grouped in Therapeutic Areas or Product Categories, and deepen easily in those articles in which you are interested with just one-click.

Where can I get a subscription?

• To identify new business enterprises Just visit our Online Store at www.pipelinereview.com

Recognize new business opportunities: joint ventures, licensing partners, co-marketing partners, etc..

• To receive news right in time

Get your personal copy every monday delivered by e-mail.

Or contact us at [email protected]

http://www.pipelinereview.com/

mailto:[email protected]

Top 20 Biologics 2007 RD Pipeline News

Documents

Transcript of Top 20 Biologics 2007 RD Pipeline News